Gastrografin

Phase 3Small molecule

Gastrografin is one of 3 small molecule programs targeting Adhesive Small Bowel Obstruction. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Adhesive Small Bowel ObstructionRecruiting

Small Bowel ObstructionUnknown status

Adhesive Small Bowel ObstructionPhase 3

Recruiting

Small Bowel ObstructionPreclinical

Unknown status

Competition

Competitive Landscape

2 competitors in Small Bowel Obstruction

#DrugCompanyPhaseTrials

Tylenol

KKenvue Brands

Approved

1 2

Gastrografin

UUniversity of California, Los Angeles

Phase 3

1 3

Extraneal

VVantive Health LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Postoperative Ileus2 trials

Gastrografin in Postoperative Ileus

Completed·UUniversity of Auckland, New Zealand·Phase 2/3·NCT01648972

Study of the Effect of Water Soluble Oral Contrast (Gastrografin) on Postoperative Ileus After Colorectal Surgery

Completed·HHospital Universitari de Bellvitge·Phase 4·NCT01440712·58 enrolled

Low Birth Weight1 trial

Impact of Oral Application of Gastrografin on the Meconium Evacuation in Very Low Birth Weight Infants

Completed·—·Phase 4·NCT01515696·96 enrolled

Adhesive Small Bowel Obstruction1 trial

Optimizing Treatment of Adhesive Small Bowel Obstruction

Recruiting·UUniversity of California, Los Angeles·Phase 3·NCT06182319·40 enrolled

Bowel Preparation1 trial

Bowel Preparation Regimen for Colon Capsule Endoscopy Procedure

Completed·RRegion Skane·Phase 3·NCT05726097·147 enrolled

Small Bowel Obstruction1 trial

The Use of Gastrografin in Chronic Radiation Enteropathy With Small Bowel Obstruction

Unknown status·JJinling Hospital, China·N/A·NCT03642288·112 enrolled

1 more indication

Gastroschisis1 trial

The Use of Gastrografin to Help Alleviate Bowel Obstruction in Gastroschisis Patients.

Withdrawn·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·Phase 4·NCT03334578

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Gastrografin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Gastrografin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Gastrografin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of California, Los Angeles company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of California, Los Angeles

Gastrografin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Postoperative Ileus2 trials

Low Birth Weight1 trial

Adhesive Small Bowel Obstruction1 trial

Bowel Preparation1 trial

Small Bowel Obstruction1 trial

Gastroschisis1 trial

References

Drug Info

Quick Facts

Related News